Our data showed significant results on NSCLC (KRAS/LKB1 mutant) insensitive rather than NSCLC (KRAS mutant) sensitive cells to JQ1 treatment, identifying the combination of JQ1 and FTH1 depletion as a potential therapeutic option for the treatment of the more aggressive NSCLC insensitive cells, enhancing the JQ1 anti‐tumor effects. Here, KRAS is linked to non-small cell lung carcinoma.